Bridgefront Capital, LLC Halozyme Therapeutics, Inc. Transaction History

Bridgefront Capital, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$36.46 - $44.03 $227,437 - $274,659	6,238 New	6,238 $238,000
Q3 2021 Nov 12, 2021	SELL	$38.47 - $46.42 $355,078 - $428,456	-9,230 Closed	0 $0
Q2 2021 Aug 12, 2021	BUY	$38.84 - $51.31 $160,875 - $212,526	4,142 Added 81.41%	9,230 $419,000
Q1 2021 May 17, 2021	SELL	$39.51 - $51.45 $273,251 - $355,828	-6,916 Reduced 57.61%	5,088 $212,000
Q4 2020 Feb 12, 2021	BUY	$25.81 - $43.62 $309,823 - $523,614	12,004 New	12,004 $513,000

543

125M

294K

180K

Ticker HALO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 139,288,992
Market Cap $6.62B
Description
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...

Get notified when there are updates to the investment portfolio of Bridgefront Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Bridgefront Capital, LLC with notifications on news.